USANA Health Sciences Stock Forecast, Price & News

-0.74 (-0.73 %)
(As of 04/21/2021 03:51 PM ET)
Today's Range
Now: $100.14
50-Day Range
MA: $99.27
52-Week Range
Now: $100.14
Volume3,373 shs
Average Volume114,160 shs
Market Capitalization$2.07 billion
P/E Ratio18.54
Dividend YieldN/A
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
USANA Health Sciences logo

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryPersonal Products
Year FoundedN/A



Sales & Book Value

Annual Sales$1.06 billion
Cash Flow$7.25 per share
Book Value$16.25 per share


Net Income$100.53 million


Market Cap$2.07 billion
Next Earnings Date4/27/2021 (Confirmed)


Seek Mentor in Pandemic, Global Author/CEO Says
April 13, 2021 |  finance.yahoo.com
USANA Dives Into Partnership With USA Swimming
April 7, 2021 |  finance.yahoo.com
Usana Health Sciences Stock Appears To Be Fairly Valued
March 28, 2021 |  finance.yahoo.com
USANA Announces Formation of Board Sustainability Committee
February 16, 2021 |  finance.yahoo.com
USNA vs. CTLT: Which Stock Is the Better Value Option?
February 11, 2021 |  finance.yahoo.com
Price Over Earnings Overview: Usana Health Sciences
February 10, 2021 |  finance.yahoo.com
See More Headlines


Overall MarketRank

1.97 out of 5 stars

Medical Sector

184th out of 2,025 stocks

Medicinals & Botanicals Industry

1st out of 33 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
-0.74 (-0.73 %)
(As of 04/21/2021 03:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

Is USANA Health Sciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than USANA Health Sciences?

Wall Street analysts have given USANA Health Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but USANA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for USANA Health Sciences

How can I listen to USANA Health Sciences' earnings call?

USANA Health Sciences will be holding an earnings conference call on Tuesday, April 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Monday, February, 8th. The company reported $1.87 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.39 by $0.48. The business had revenue of $310.50 million for the quarter, compared to analyst estimates of $286.71 million. USANA Health Sciences had a net margin of 10.57% and a trailing twelve-month return on equity of 32.91%. The company's quarterly revenue was up 14.4% on a year-over-year basis. During the same period last year, the company earned $1.41 earnings per share.
View USANA Health Sciences' earnings history

How has USANA Health Sciences' stock been impacted by COVID-19?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, USNA shares have increased by 43.5% and is now trading at $100.27.
View which stocks have been most impacted by COVID-19

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 9th 2021, which permits the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 8.2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences updated its FY21 earnings guidance on Tuesday, February, 9th. The company provided earnings per share (EPS) guidance of $6.00-$6.45 for the period, compared to the Thomson Reuters consensus estimate of $5.56. The company issued revenue guidance of $1.21-$1.27 billion, compared to the consensus revenue estimate of $1.17 billion.

What price target have analysts set for USNA?

2 Wall Street analysts have issued 12-month target prices for USANA Health Sciences' shares. Their forecasts range from $126.00 to $126.00. On average, they expect USANA Health Sciences' share price to reach $126.00 in the next year. This suggests a possible upside of 25.7% from the stock's current price.
View analysts' price targets for USANA Health Sciences
or view top-rated stocks among Wall Street analysts.

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:
  • Mr. Kevin G. Guest, Chairman & CEO (Age 58, Pay $1.39M)
  • Mr. Jim Brown, Pres (Age 52, Pay $905.81k)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 51, Pay $641.25k)
  • Mr. Walter Noot, Chief Operating Officer (Age 55, Pay $644.22k)
  • Mr. David Mulham, Chief Sales Officer (Age 61, Pay $678.89k)
  • Dr. Myron W. Wentz, Founder & Chairman Emeritus (Age 80)
  • Dr. John Cuomo, Exec. Director of Product Devel. & Technology
  • Dr. Robert A. Sinnott, Chief Scientific Officer (Age 56)
  • Mr. Patrique Richards, Exec. Director of Investor Relations & Bus. Devel.
  • Mr. P. Joshua Foukas, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 45)

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of USANA Health Sciences' key competitors?

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.08%), Pacer Advisors Inc. (0.08%), State of Alaska Department of Revenue (0.04%), Louisiana State Employees Retirement System (0.03%), Oregon Public Employees Retirement Fund (0.02%) and Everence Capital Management Inc. (0.01%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences

Which institutional investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Louisiana State Employees Retirement System. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences
or view top insider-selling stocks.

Which institutional investors are buying USANA Health Sciences stock?

USNA stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Pacer Advisors Inc., Everence Capital Management Inc., Prairiewood Capital LLC, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for USANA Health Sciences
or or view top insider-buying stocks.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $100.27.

How much money does USANA Health Sciences make?

USANA Health Sciences has a market capitalization of $2.07 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis.

How many employees does USANA Health Sciences have?

USANA Health Sciences employs 1,943 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

Where are USANA Health Sciences' headquarters?

USANA Health Sciences is headquartered at 3838 West Parkway Blvd, Salt Lake City UT, 84120.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]

This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.